UCLA researchers reported proof-of-concept results showing enhancer-targeted CRISPR activation can rescue gene expression and cellular phenotypes in organoid models of autism. Published in Nature Neuroscience, the study used a catalytically inactive Cas9 fused to p300 (dCas9-p300) to activate fetal-brain enhancers without cutting DNA. The authors targeted high-confidence autism genes CHD8 and SCN2A in patient-derived excitatory neurons and cerebral forebrain organoids. In CHD8-mutant models, CRISPR activation reduced organoid overgrowth and shifted gene-expression patterns toward wild-type; in SCN2A-mutant neurons, it restored excitability toward wild-type firing levels. While preclinical, the approach directly addresses dosage sensitivity concerns for haploinsufficient neurodevelopmental disorders.
Get the Daily Brief